Health & Medicinereview2026-11-15

COMPARATIVE EFFICACY AND SAFETY OF ANTICOAGULATION STRATEGIES FOR ELECTRICAL CARDIOVERSION OF ATRIAL FIBRILLATION: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Open access0 citations

Abstract

Introduction: Electrical cardioversion (ECV) is the most effective method for restoring sinus rhythm in atrial fibrillation (AF), but it transiently amplifies the risk of thromboembolism through atrial stunning and a post-conversion prothrombotic state. Several anticoagulation strategies coexist in contemporary practice: dose-adjusted vitamin K antagonists (VKA) with or without heparin bridging, non-vitamin K antagonist oral anticoagulants (NOAC), imaging-guided early versus conventional delayed cardioversion, and, in acute-onset AF, cardioversion without periprocedural anticoagulation. Their comparative efficacy and safety have not been integrated within a single quantitative framework that combines randomized and real-world evidence. We therefore aimed to compare these strategies with respect to thromboembolism, bleeding, mortality, and pre-cardioversion left atrial thrombus. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. PubMed, Europe PMC, Google Scholar, Semantic Scholar, and ClinicalTrials.gov were searched for reports published between January 2011 and October 2026. Randomized controlled trials (RCTs), RCT-derived cardioversion analyses, comparative cohort studies, and case series of adults undergoing ECV for AF or atrial flutter were eligible. Risk of bias was assessed with RoB 2, ROBINS-I, and the JBI checklist for case series. Risk ratios (RR) were pooled with DerSimonian–Laird random-effects models, complemented by Mantel–Haenszel fixed-effect, Peto, and Hartung–Knapp–Sidik–Jonkman (HKSJ) analyses with prediction intervals; adjusted estimates were pooled by generic inverse variance and single-arm incidences by the Freeman–Tukey transformation. Certainty of evidence was graded with GRADE. Results: Thirty-five studies (42 reports) were included: 8 RCTs or RCT-derived analyses, 20 comparative cohorts, and 7 case series, encompassing 93,271 patients or cardioversion procedures. Compared with VKA, NOAC-based anticoagulation yielded a similar risk of stroke or systemic embolism (RR 0.90; 95% CI 0.65–1.26; 18 studies; I² = 0%), with a numerically lower estimate in randomized evidence (RR 0.60; 95% CI 0.27–1.35). Major bleeding was reduced (RR 0.66; 95% CI 0.45–0.96; 17 studies; absolute difference -1.6 per 1,000 cardioversions), a benefit driven by observational cohorts and attenuated in randomized trials (RR 0.91; 95% CI 0.49–1.70). In dedicated cardioversion RCTs, the trial-defined efficacy composite was lower with NOAC (RR 0.43; 95% CI 0.21–0.87), and ischaemic stroke was reduced (RR 0.10; 95% CI 0.01–0.77; 2 RCTs). All-cause mortality did not differ (RR 0.74; 95% CI 0.32–1.68). Treatment effects were consistent across early/transoesophageal echocardiography (TEE)-guided and delayed strategies (P for interaction = 0.80), individual NOACs (P = 0.38), and prior anticoagulant exposure (P = 0.55). Imaging-guided/early cardioversion was not associated with different thromboembolic risk compared with conventional delayed cardioversion (RR 0.88; 95% CI 0.41–1.90). Periprocedural oral anticoagulation, compared with none, reduced thromboembolism by 63% (RR 0.37; 95% CI 0.28–0.49; 7 studies; I² = 0%). Pooled post-cardioversion thromboembolic incidence was 0.17% with NOAC, 0.32% with VKA, and 0.45% without anticoagulation. Certainty of evidence ranged from low to very low. Discussion: NOAC-based strategies provide thromboembolic protection at least equivalent to well-managed VKA during ECV, with a favourable but design-dependent bleeding signal and practical advantages that permit earlier cardioversion. The protective effect of periprocedural anticoagulation is large and consistent, including in acute-onset AF, whereas the choice between imaging-guided early and conventional delayed timing does not appear to modify thromboembolic risk when therapeutic anticoagulation is ensured. Conclusion: Uninterrupted therapeutic anticoagulation, preferably with a NOAC, should accompany every electrical cardioversion of AF irrespective of AF duration in patients with thromboembolic risk factors, either for at least 3 weeks before cardioversion or with imaging exclusion of left atrial thrombus, and for at least 4 weeks afterwards. Adequately powered randomized trials of strategy timing, reduced-dose regimens, and acute-onset AF are still required.

// Source

View paper (DOI)Open access versionOpenAlexThe Indonesian Journal of General MedicinePublished 2026-11-15

Authors: Angga Rifqi Mujidiatama, Muhammad Ogan Islakhul Idham, Azatil Ishmah Matdoan, Juchairah Faradillah Sangadji, Jansen Hadinata Soetanto

Institutions: Universitas Pattimura, University of Brawijaya, Udayana University